68Ga-FAPI + 18F-FDG

This is a combination of two radiopharmaceutical PET imaging agents used in oncology and other disease diagnostics. - **68Ga-FAPI** (Gallium-68–labeled fibroblast activation protein inhibitor) targets the fibroblast activation protein (FAP), which is highly expressed in cancer-associated fibroblasts within the tumor stroma. It enables visualization of tumors with strong desmoplastic reactions and fibrotic or inflammatory processes, offering high contrast due to low background uptake in normal tissues such as brain, liver, and oral mucosa. The DOTA chelator allows for potential theranostic applications by coupling with therapeutic radionuclides[1][2][4][5]. - **18F-FDG** (Fluorine-18 fluorodeoxyglucose) is a glucose analog that accumulates in cells with increased glycolytic activity—commonly used as the standard PET tracer for oncologic imaging. The combination of these tracers can provide complementary information: - **68Ga-FAPI** highlights tumor stroma/fibroblastic activity. - **18F-FDG** highlights metabolic activity. This dual-tracer approach may improve detection sensitivity and specificity for various cancers (e.g., lung, pancreatic, head and neck), especially where one tracer alone may be limited by background uptake or specific tumor biology[1][2][4][5].

Other names

Gallium-68 FAPI + Fluorine-18 FDGGallium-68 fibroblast activation protein inhibitor plus fluorodeoxyglucoseGallium68 fibroblast activation protein inhibitor plus fluorodeoxyglucoseGallium 68 fibroblast activation protein inhibitor plus fluorodeoxyglucose